Waverley Pharma Inc (WAVE) - Total Assets
Based on the latest financial reports, Waverley Pharma Inc (WAVE) holds total assets worth CA$1.19 Million CAD (≈ $864.14K USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Waverley Pharma Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Waverley Pharma Inc - Total Assets Trend (2015–2025)
This chart illustrates how Waverley Pharma Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Waverley Pharma Inc for real-time trading data and today's change.
Waverley Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Waverley Pharma Inc's total assets of CA$1.19 Million consist of 33.8% current assets and 66.2% non-current assets. Explore how liquid is Waverley Pharma Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 3.6% |
| Accounts Receivable | CA$32.66K | 2.6% |
| Inventory | CA$306.28K | 24.6% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$325.50K | 26.2% |
| Goodwill | CA$212.95K | 17.1% |
Asset Composition Trend (2015–2025)
This chart illustrates how Waverley Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Waverley Pharma Inc's current assets represent 33.8% of total assets in 2025, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 3.6% of total assets in 2025, down from 100.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 43.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 26.2% of total assets.
Waverley Pharma Inc Competitors by Total Assets
Key competitors of Waverley Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥7.07 Billion |
|
Nanobiotix S.A
PA:NANO
|
France | €45.17 Million |
|
Savara Inc
NASDAQ:SVRA
|
USA | $192.14 Million |
Waverley Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 0.15 | 1.10 |
| Quick Ratio | 0.03 | 0.07 | 0.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-3.34 Million | CA$-2.86 Million | CA$133.93K |
Waverley Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Waverley Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | -39.2% |
| Total Assets | CA$1.24 Million |
| Market Capitalization | $390.63K USD |
Valuation Analysis
Below Book Valuation: The market values Waverley Pharma Inc's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Waverley Pharma Inc's assets decreased by 39.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Waverley Pharma Inc (2015–2025)
The table below shows the annual total assets of Waverley Pharma Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$1.24 Million ≈ $900.14K |
-39.18% |
| 2024-12-31 | CA$2.05 Million ≈ $1.48 Million |
+114.83% |
| 2023-12-31 | CA$952.29K ≈ $688.87K |
-64.56% |
| 2022-12-31 | CA$2.69 Million ≈ $1.94 Million |
-27.05% |
| 2021-12-31 | CA$3.68 Million ≈ $2.66 Million |
+5.50% |
| 2020-12-31 | CA$3.49 Million ≈ $2.53 Million |
-20.53% |
| 2019-12-31 | CA$4.39 Million ≈ $3.18 Million |
-16.10% |
| 2018-12-31 | CA$5.24 Million ≈ $3.79 Million |
-21.35% |
| 2017-12-31 | CA$6.66 Million ≈ $4.82 Million |
+6657768.00% |
| 2016-12-31 | CA$100.00 ≈ $72.34 |
0.00% |
| 2015-12-31 | CA$100.00 ≈ $72.34 |
-- |
About Waverley Pharma Inc
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharm… Read more